Trusted Resources: News & Meetings
Latest announcements and gatherings
Sanfilippo Ideal for FDA’s Accelerated Approval Pathway, Foundation Says
The Cure Sanfilippo Foundation is encouraging the U.S. Food & Drug Administration (FDA) to consider Sanfilippo syndrome as a candidate for the agency’s accelerated approval pathway. According to a recent foundation-led study, families of Sanfilippo children are willing to accept modest treatment benefits even if they come with risks.
“Doing nothing is the biggest risk in Sanfilippo!” Glenn O’Neill, foundation president and father to a Sanfilippo child, said in a press release. His statement came at the end of a presentation Oct. 20 at the 13th Annual Rare Disease Scientific Workshop.
The FDA’s Accelerated Approval Program allows for earlier approval of therapies that treat serious conditions and fill an unmet medical need. Sanfilippo syndrome, or mucopolysaccharidosis type III (MPS III), is a rare genetic disorder characterized by the mutations in genes that encode enzymes that break down the complex sugar molecule known as heparan sulfate.
BookmarkRelated Content
-
Real-World Data Assessment of Safety of Home-Based and Hospital/Outpatient-Based laronidase Enzyme Replacement Thera...Enzyme replacement therapy (ERT) is avai...
-
Believe in G Golf TournamentGianna, was diagnosed with Sanfilippo Sy...
-
Schizophreniform Presentation and Abrupt Neurologic Decline in a Patient With Late-Onset Mucopolysaccharidosis Type ...Due to their low frequency and some atyp...
-
Boston Children’s – Lysosomal Storage Disease Program (BoLD)The Boston Children's Lysosomal Storage ...
-
Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the ArtThe need for long-lasting and transforma...
-
The Surgical Management of Spinal Disorders in Lysosomal Storage Diseases: A Systematic ReviewThe skeletal manifestations of lysosomal...
-
UPMC Children’s Hospital of Pittsburgh – Center for Rare Disease TherapyHurler syndrome (mucopolysaccharidosis t...
Powered by
